Clostridium difficile colitis: Review of the therapeutic approach

American Journal of Therapeutics

Volumn 21, Issue 5, 2014, Pages 385-394

  Joseph, Josmi ^a   Singhal, Shashideep ^a   Patel, Gia M ^a   Anand, Sury ^a  

^a BROOKLYN HOSPITAL CENTER   (United States)

Author keywords

Antibiotics; Clostridium difficile; Colitis; Management; Refractory; Treatment

Indexed keywords

BACITRACIN; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; VANCOMYCIN; AMINOGLYCOSIDE; DEPSIPEPTIDE; RIFAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLOSTRUM; FECAL TRANSPLANTATION; HUMAN; IMMUNIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT INFECTION; REVIEW; TRANSPLANTATION; CLOSTRIDIUM INFECTIONS; COLITIS; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

AMINOGLYCOSIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DEPSIPEPTIDES; HUMANS; METRONIDAZOLE; PROBIOTICS; RECURRENCE; RIFAMYCINS; VANCOMYCIN;

EID: 84912031935     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318245992d     Document Type: Review

References (95)

1. Kelly CP, Kyne L. The host immune response to Clos-tridium difficile. J Med Microbiol. 2011;60:1070-1079.
2. Kyne L, Hamel MB, Polavaram R, et al. Healthcare costs and mortality associated with healthcare-associated diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
3. Hsu J, Abad C, Dinh M, et al. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010;105: 2327-2339.
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
5. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758-764.
6. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171:466-472.
7. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhea. QJM. 2004;97:423-429.
8. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35: 208-210.
9. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040-2049.
10. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, riskfactors and management. Nat Rev Gas-troenterol Hepatol. 2011;8:17-26.
11. Kim JW, Lee KL, Jeong JB, et al. Protonpump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16: 3573-3577.
12. Morales Chamorro R, Serrano Blanch R, Mendez Vidal MJ, et al. pseudomembranouscolitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005;7:258-261.
13. Gorschluter M, Glasmacher A, Hahn C, et al. Clostrid-ium difficile infection in patients with neutropenia. Clin Infect Dis. 2001;33:786-791.
14. Keighley MR, Burdon DW, Alexander-Williams J, et al. Diarrhoea and pseudomembranous colitis after gastrointestinal operations: a prospective study. Lancet. 1978;2:1165-1167.
15. Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol. 2009;27:289-300.
16. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudo-membranous colitis. Am J Gastroenterol. 1985;80:867-868.
17. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S12-S18.
18. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCr ribo-type 027 and recognition of specific risk factors. Clin Microbiol Infect. 2009;15:427-434.
19. You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632-633.
20. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003; 24:699-706.
21. Drudy D, Harnedy N, Fanning S, et al. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect. 2007;13:298-304.
22. Yeom CH, Cho MM, Baek SK, et al. Risk factors for the development of Clostridium difficile-associated colitis after colorectal cancer surgery. J Korean Soc Coloproctol-ogy. 2010;26:329-333.
23. Kyne L, Merry C, O'Connell B, et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing. 1999;28:107-113.
24. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
25. Velazquez-Gomez I, Rocha-Rodriguez R, Toro DH, et al. A severity score index for Clostridium difficile infection. Infect Dis Clin Pract. 2008;16:376-378.
26. Lamp KC, Freeman CD, Klutman NE, et al. Pharmaco-kinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36:353-373.
27. Hu MY, Maroo S, Kyne L, et al. A prospective study of risk factorsand historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hep-atol. 2008;6:1354-1360.
28. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40: 1586-1590.
29. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacoki-netics of vancomycin. Clin Pharmacokinet. 1986;11:257-282.
30. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridiumdifficile-associated diarrhea, stratified bydisease severity. Clin Infect Dis. 2007;45:302-307.
31. Pepin J, Valiquette L, Gagnon S, et al. Outcomes of Clos-tridium difficile-associated disease treated with metroni-dazole or vancomycin before and after the emergence of NAP 1/027. Am J Gastroenterol. 2007;102:2781-2788.
32. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral van-comycin: comparison of two dosage regimens. Am J Med. 1989;86:15-19.
33. Murray BE. Problems and perils of vancomycin resistant enterococci. Braz J Infect Dis. 2000;4:9-14. Review.
34. Kapoor K, Chandra M, Nag D, et al. Evaluation of met-ronidazole toxicity: a prospective study. Int J Clin Pharmacol Res. 1999;19:83-88.
35. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2386-2388.
36. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect. 1998;38:93-100.
37. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clos-tridium difficile disease. Am J Gastroenterol. 2002;97: 1769-1775.
38. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403-410.
39. Ackermann G, Löffler B, Adler D, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004;48:2280-2282.
40. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother. 2004;48: 4898-4902.
41. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51:2716-2719.
42. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. OPT-80-003 Clinical Study Group. N Engl J Med. 2011; 364:422-431.
43. Latella G, Scarpignato C. Rifaximin in the management of colonic diverticular disease. Expert Rev Gastroenterol Hepatol. 2009;3:585-598.
44. Patrick Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol. 2010;3:221-225.
45. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
46. Johnson S, Schriever C, Patel U, et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15:290-291.
47. Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipogly-codepsipeptide antibiotic. Ann Pharmacother. 2005;39: 863-868.
48. Peláez T, Alcalá L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Che-mother. 2005;49:1157-1159.
49. Pullman J, Prieto J, Leach TS. Ramoplanin vs vancomy-cin in the treatment of Clostridium difficile diarrhea: a phase II study [abstract]. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC.
50. Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodep-sipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006;4:939-945.
51. Musher DM, Logan N, Hamill R, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421-427.
52. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009; 48:E41-E46.
53. Musher DM, Logan N, Mehendiratta V, et al. Clostrid-ium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemo-ther. 2007;59:705-710.
54. Barreto ARF, Cavalcante IC, Castro MV, et al. Fucoidin prevents Clostridium difficile toxin-A-induced ileal enteritis in mice. Dig Dis Sci. 2008;53:990-996.
55. Odenholt I, Walder M, Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. Chemotherapy. 2007;53:267-274.
56. Cronberg S, Castor B, Thorén A. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clos-tridium difficile. Infection. 1984;12:276-279.
57. Wistrom J. Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin: a dose finding study. Scand J Infect Dis. 1994;26:309-316.
58. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2007;(3):CD004610.
59. Hedge DD, Strain JD, Heins JR, et al. New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag. 2008;4:949-964.
60. Moncino MD, Falletta JM. Multiple relapses of Clostrid-ium difficile-associated diarrhea in a cancer patient. Am J Pediatr Hematol Oncol. 1992;14:361-364.
61. Ariano RE, Zhanel GG, Harding GK. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. CMAJ. 1990;142:1049-1051.
62. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg. 1982;69:137-139.
63. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tole-vamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J. 2004;87:534-539.
64. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother. 2001;45: 2340-2347.
65. Louie TJ, Peppe J, Watt CK, et al. Tolevamer Study Investigator Group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:411-420.
66. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother. 2009;53:2202-2204.
67. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74:6339-6347.
68. Dawson AE, Shumak SL, Redelmeier DA. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:1445-1446.
69. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197-205.
70. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clos-tridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41: 1254-1260.
71. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856. Review.
72. Saito T, Kimura S, Tateda K, et al. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother. 2011;66:1096-1099.
73. Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med. 2010;5:E1-E9.
74. Dallas SD, Rolfe RD. Binding of Clostridium difficile toxin A to human milk secretory component. J Med Microbiol. 1998;47:879-888.
75. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tole-vamer. Int J Antimicrob Agents. 2009;33:4-7.
76. Kelly CP, Chetham S, Keates S, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother. 1997;41:236-241.
77. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008; 52:4163-4165.
78. Kokkotou E, Moss AC, Michos A, et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008;52:1121-1126.
79. Orrhage K, Sjöstedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother. 2000;46:603-612.
80. Hopkins MJ, Macfarlane GT. Nondigestible oligosacchar-ides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol. 2003;69:1920-1927.
81. Shanholtzer CJ, Willard KE, Holter JJ, et al. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol. 1992;30:1837-1840.
82. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of ommensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229-241.
83. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2003;17:755-773.
84. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gas-troenterol. 2004;38:475-483.
85. Sullivan A, Nord CE. Probiotics in human infections. J Antimicrob Chemother. 2002;50:625-627.
86. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-1597.
87. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepa-tol. 2010;8:471-473.
88. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol. 2009;25:24-35.
89. Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudo-membraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981;47:178-183.
90. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival in patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267-272.
91. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gas-troenterol Hepatol. 2010;4:589-600. Review.
92. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
93. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106-113.
94. Grewal NS, Salim A. Clostridium difficile colitis: a call for aggressive management. Scand J Surg. 2010;99:90-92.
95. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorec-tal Dis. 2006;8:149-154.